These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4838924)

  • 1. The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones.
    Jorgensen FS; Brünner S
    Scand J Urol Nephrol; 1974; 8(2):128-31. PubMed ID: 4838924
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of bendroflumethiazide on the renal handling of calcium, magnesium and phosphate in normocalcaemic renal stone formers and in hyperparathyroidism.
    Jorgensen FS; Transbol I
    Acta Med Scand; 1973 Oct; 194(4):327-34. PubMed ID: 4749172
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers.
    Ahlstrand C; Tiselius HG; Larsson L; Hellgren E
    Br J Urol; 1984 Jun; 56(3):255-62. PubMed ID: 6399984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones.
    Ljunghall S; Backman U; Danielson BG; Fellström B; Johansson G; Odlind B; Wikström B
    J Urol; 1982 Jun; 127(6):1207-10. PubMed ID: 7087040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of therapy with bendroflumethiazide in patients with recurrent renal calcium stones.
    Backman U; Danielson BG; Johansson G; Ljunghall S; Wikström
    Br J Urol; 1979 Jun; 51(3):175-80. PubMed ID: 465983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention.
    Pucci ND; Marchini GS; Mazzucchi E; Reis ST; Srougi M; Evazian D; Nahas WC
    Int Braz J Urol; 2018; 44(4):758-764. PubMed ID: 29617079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide.
    Ahlstrand C; Tiselius HG
    Br J Urol; 1984 Apr; 56(2):125-30. PubMed ID: 6498431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do thiazides prevent recurrent idiopathic renal calcium oxalate stones?
    Wolf H; Brocks P; Dahl C
    Proc Eur Dial Transplant Assoc; 1983; 20():477-80. PubMed ID: 6361755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol treatment of uric-acid disorders in calcium-stone formers.
    Coe FL; Raisen L
    Lancet; 1973 Jan; 1(7795):129-31. PubMed ID: 4118468
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of triamterene on the renal clearance of calcium, magnesium, phosphate, and uric acid in man.
    Walker BR; Hoppe RC; Alexander F
    Clin Pharmacol Ther; 1972; 13(2):245-50. PubMed ID: 4552822
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship of the urinary cations, Calcium, Magnesium, Sodium and Potassium, in patients with Renal Calculi.
    Welshman SG; McGeown MG
    Br J Urol; 1975 Jun; 47(3):237-42. PubMed ID: 1139114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. II. Estimating biological components of variation.
    Harris EK; Kanofsky P; Shakarji G; Cotlove E
    Clin Chem; 1970 Dec; 16(12):1022-7. PubMed ID: 5481562
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preventive therapy in patients with recurrent kidney calculi].
    Backman U; Danielson BG; Johansson G; Ljunghall S
    Lakartidningen; 1978 May; 75(19):1917-8. PubMed ID: 651452
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary crystalloid excretion in patients with inflammatory bowel disease.
    Breuer RI; Gelzayd EA; Kirsner JK
    Gut; 1970 Apr; 11(4):314-8. PubMed ID: 5428854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3. Physiological and medical implications.
    Cotlove E; Harris EK; Williams GZ
    Clin Chem; 1970 Dec; 16(12):1028-32. PubMed ID: 5481563
    [No Abstract]   [Full Text] [Related]  

  • 17. The urinary excretion and serum concentration of calcium, magnesium, sodium and phosphate in male patients with recurring renal stone formation.
    Jorgensen FS
    Scand J Urol Nephrol; 1975; 9(3):243-8. PubMed ID: 1209181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones.
    Mortensen JT; Schultz A; Ostergaard AH
    Int Urol Nephrol; 1986; 18(3):265-9. PubMed ID: 3533825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent thiazide therapy in recurrent stone formers.
    Rundle JS; Scott R
    Urology; 1980 Nov; 16(5):464-6. PubMed ID: 7445281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
    Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
    Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.